Boehringer Ingelheim’s Atrovent
Executive Summary
Ipratroprium .02% inhalation solution for nebulization approved Sept. 29. NDA for new dosage form of bronchodilator was submitted in October 1991; the solution will be supplied in 2.5 ml unit-dose vials. Drug is indicated for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.